LabCorp's $85M Orchid Deal Depends On Divestment: FTC

Law360, New York (December 8, 2011, 5:04 PM EST) -- The Federal Trade Commission has asked Laboratory Corp. of America Holdings to divest a part of Orchid Cellmark Inc.’s paternity testing business in order to have its $85 million purchase of the rival DNA testing company approved, the agency said Thursday.

The FTC said it imposed the condition as part of a proposed agreement with the companies to resolve its complaint claiming that North Carolina-based LabCorp's April-announced acquisition of Orchid would have an anti-competitive effect on the paternity testing services market that government agencies rely on....
To view the full article, register now.